BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 200 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,233,496 | +3.1% | 846,844 | -15.3% | 0.01% | 0.0% |
| Q1 2024 | $5,076,751 | +2.5% | 999,316 | +20.9% | 0.01% | 0.0% |
| Q4 2023 | $4,951,435 | -24.6% | 826,617 | -10.9% | 0.01% | -25.0% |
| Q3 2023 | $6,567,776 | +18.9% | 927,652 | +18.2% | 0.01% | +14.3% |
| Q2 2023 | $5,525,056 | +9.6% | 784,809 | +29.8% | 0.01% | +16.7% |
| Q1 2023 | $5,040,787 | -42.8% | 604,411 | -21.2% | 0.01% | -50.0% |
| Q4 2022 | $8,805,331 | +11.3% | 767,015 | +22.1% | 0.01% | +9.1% |
| Q3 2022 | $7,913,153 | +31.4% | 628,028 | +10.3% | 0.01% | -26.7% |
| Q2 2022 | $6,023,000 | +402.8% | 569,149 | +672.6% | 0.02% | +650.0% |
| Q1 2022 | $1,198,000 | +21.4% | 73,666 | +3.3% | 0.00% | 0.0% |
| Q4 2021 | $987,000 | -0.8% | 71,302 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $995,000 | -10.9% | 69,218 | -2.1% | 0.00% | 0.0% |
| Q2 2021 | $1,117,000 | +41.6% | 70,669 | -9.0% | 0.00% | 0.0% |
| Q1 2021 | $789,000 | +38.2% | 77,630 | +1.3% | 0.00% | +100.0% |
| Q4 2020 | $571,000 | +182.7% | 76,661 | +30.4% | 0.00% | – |
| Q3 2020 | $202,000 | -19.8% | 58,775 | +11.0% | 0.00% | -100.0% |
| Q2 2020 | $252,000 | +61.5% | 52,955 | -32.1% | 0.00% | – |
| Q1 2020 | $156,000 | -37.3% | 78,010 | +8.0% | 0.00% | -100.0% |
| Q4 2019 | $249,000 | +90.1% | 72,238 | +58.4% | 0.00% | – |
| Q3 2019 | $131,000 | -24.3% | 45,599 | 0.0% | 0.00% | – |
| Q2 2019 | $173,000 | -53.4% | 45,599 | 0.0% | 0.00% | -100.0% |
| Q1 2019 | $371,000 | +0.8% | 45,599 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $368,000 | +14.3% | 45,599 | +8.2% | 0.00% | 0.0% |
| Q3 2018 | $322,000 | +33.1% | 42,157 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $242,000 | +20.4% | 42,157 | 0.0% | 0.00% | – |
| Q1 2018 | $201,000 | -2.9% | 42,157 | 0.0% | 0.00% | – |
| Q4 2017 | $207,000 | +3.0% | 42,157 | +10.1% | 0.00% | – |
| Q3 2017 | $201,000 | -5.6% | 38,275 | 0.0% | 0.00% | – |
| Q2 2017 | $213,000 | -25.8% | 38,275 | +12.1% | 0.00% | -100.0% |
| Q1 2017 | $287,000 | +32.9% | 34,148 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $216,000 | +43.0% | 34,148 | 0.0% | 0.00% | – |
| Q3 2016 | $151,000 | +55.7% | 34,148 | 0.0% | 0.00% | – |
| Q2 2016 | $97,000 | 0.0% | 34,148 | 0.0% | 0.00% | – |
| Q1 2016 | $97,000 | -72.4% | 34,148 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $352,000 | -9.5% | 34,148 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $389,000 | -35.2% | 34,148 | -15.0% | 0.00% | 0.0% |
| Q2 2015 | $600,000 | +65.3% | 40,197 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $363,000 | -25.8% | 40,197 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $489,000 | +24.4% | 40,197 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $393,000 | -23.4% | 40,197 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $513,000 | – | 40,197 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |